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8 Introduction. Bipolar disorder (BD) is a chronic, highly disabling condition associated with psychiatric/medical
9 comorbidity and substantive morbidity, mortality, and suicide risks. In prior reports, varying parameters have been
10 associated with suicide risk.
11 Objectives. To evaluate sociodemographic and clinical variables characterizing Italian individuals with BD with versus
12 without prior suicide attempt (PSA).
13 Methods. A sample of 362 Italian patients categorized as BD according to the Diagnostic and Statistical Manual of
14 Mental Disorders, Fourth Edition, Text Revision (DSM IV-TR) was assessed and divided in 2 subgroups: with and
15 without PSA. Sociodemographic and clinical variables were compared between prior attempters and non-attempters
16 using corrected multivariate analysis of variance (MANOVA).
17 Results. More than one-fourth of BD patients (26.2%) had a PSA, with approximately one-third (31%) of these
18 having> 1 PSA. Depressive polarity at onset, higher number of psychiatric hospitalizations, comorbid alcohol abuse,
19 comorbid eating disorders, and psychiatric poly-comorbidity were significantly more frequent (p< .05) in patients with
20 versus without PSA. Additionally, treatment with lithium, polypharmacotherapy (≥ 4 current drugs) and previous
21 psychosocial rehabilitation were significantly more often present in patients with versus without PSA.
22 Conclusions.We found several clinical variables associated with PSA in BD patients. Even though these retrospective
23 findings did not address causality, they could be clinically relevant to better understanding suicidal behavior in BD and
24 adopting proper strategies to prevent suicide in higher risk patients.
25
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28 Introduction
29 Bipolar disorder (BD) includes different chronic, often
30 comorbid, and highly disabling conditions that are
31 responsible, in the most severe cases, for a high burden
32 of morbidity and mortality, often related to suicidal
33 behavior. In this respect, the International Society for
34 Bipolar Disorder Task Force, in a recent systematic
35 review of studies from 1980 to 2014, reported a pooled
36 suicide rate for bipolar patients of 164 per 100.000
37person-years,1 a rate 10- to 30-fold higher compared to
38the general population.2
39In a previous study of 176.347 patients with varying
40psychiatric diseases who were referred for secondary
41mental health services, the absolute risk of suicide in
42BD patients was approximately 8% for men and 5% for
43women over a median of 18 years of follow-up.3
44With respect to suicide attempts in BD, studies have
45reported that 20%–50% of patients suffering from BD
46had a prior suicide attempt (PSA),4–7 with risk being
47higher in younger patients and during the first years after
48diagnosis.8
49Recognizing risk factors associated with suicide and,
50therefore, being able to adopt proper strategies to
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51 predict it are of particular importance for clinicians
52 involved in the management of bipolar patients. In a
53 recent report from our group, BD patients with
54 depressive versus elevated polarity at onset more
55 frequently had PSA.9 Several additional risk factors have
56 been previously linked to suicide in the bipolar popula-
57 tion, but PSA in particular is consistently reported to be
58 one of the main risk factors implicated in suicidal
59 behavior.10–12 Of note, death by suicide was predicted
60 by PSA in at least 50% of the cases.13
61 Other factors associated with PSA in BD patients
62 include early age at onset13–16; long duration of illness15,16;
63 long duration of untreated illness (DUI)16,17; positive
64 family history for suicide14,18–20; higher lifetime number
65 of hospitalizations21; comorbid alcohol/substance
66 use4,15,16; eating,16 anxiety,4 and personality (parti-
67 cularly Cluster B) disorders20; presence of complex
68 psychopharmacological therapy; and absence of treat-
69 ment.11 Among sociodemographic variables, female
70 gender4,15,16,22 and single marital status in bipolar
71 disorder I (BD-I) patients23 were associated with PSA.
72 Despite the above-mentioned findings, suicidal beha-
73 vior remains very difficult to predict.24 The causes are
74 complex and multiple, and each factor adds only a
75 small amount to overall risk, particularly in light of the
76 correlation between genetic and environmental
77 factors.25 Moreover, it is difficult to determine whether
78 a single factor is associated with a higher suicidal risk
79 per se or due to the presence of BD, since some features
80 of PSA among bipolar patients partially overlap with
81 those of PSA observed in patients who suffer from other
82 psychiatric disorders and in the general population.11
83 In the present study, we assessed sociodemographic
84 and clinical variables in Italian BD patients with versus
85 without PSA, with the aim of better characterizing
86 suicidal behavior in the BD population.
87Methods
88The study included 362 bipolar patients, who were
89recruited at the University Department of Mental Health
90at the Fondazione IRCCS Ca’ Granda, Ospedale Mag-
91giore Policlinico in Milan, Italy. In order to depict a
92better representation of the phenomenology of Italian
93BD patients living in the Milan metropolitan area,
94patients referred by community-based psychiatric ser-
95vices were also included. Written informed consent was
96obtained from all participants, after the description of
97the study, in order to have their clinical charts reviewed
98for research purposes.
99The Structured Clinical Interviews forDiagnostic and
100Statistical Manual of Mental Disorders, Fourth Edition,
101Text Revision (SCID I and II),26–28 were administered to
102all participants by psychiatrists or residents in psychiatry
103with a specific training in mood disorders in order to
104confirm Axis I/II diagnoses and detect any comorbid
105psychiatric condition(s). To increase diagnostic specifi-
106city, only individuals with BD-I or bipolar disorder II
107(BD-II) and not those with BD Not Otherwise Specified
108were included in the study sample. In case of comorbidity
109with another psychiatric disorder, BD had to be the
110primary diagnosis affecting patient’s everyday function-
111ing and being mostly responsible for its impact on quality
112of life and for help-seeking. Patients with evidence of
113mental retardation, neurological disorders, organic
114mental illnesses, or other disabling medical conditions
115were excluded.
116Sociodemographic variables included age, gender,
117education, employment, cohabitation, and marital sta-
118tus. Clinical variables included: diagnosis; age at onset
119(AAO, ie, age of first mood episode of any polarity), with
120a categorical distinction between childhood/adolescent
121onset (< 18 years old) and adult onset (≥ 18 years old);
122duration of illness; DUI; polarity of first episode
123[depressed or elevated (manic, hypomanic, or mixed)];
124duration of most recent episode; lifetime number of
125psychiatric hospitalizations and involuntary commit-
126ments; presence of psychiatric disorders in the family
127(first- and second-degree relatives); presence of lifetime
128psychosis; current subthreshold symptoms; stressful life
129events before onset; cross-sectional and lifetime psychia-
130tric and medical comorbidity; and history of psychosocial
131rehabilitation (ie, community-based interventions aimed
132at improving patients’ social/working skills, reducing
133functional disability, and improving quality of life).29
134In order to evaluate patients’ current level of global
135functioning, the Global Assessment of Functioning
136(GAF)30 was administered after the resolution of the last
137syndromic mood episode in order to exclude potential
138current mood state-related bias.
139Data related to lifetime number, methods used (eg, self-
140poisoning, cutting, jumping, or others), and severity of PSA
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FIGURE 1. Continuous clinical variables found to be statistically different
between patients with and without prior suicide attempt (PSA). All data are
expressed in percentage. *p< .05.
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141 were collected. PSAs were considered clinically serious if a
142 medical or surgical intervention was necessary and if PSAs
143 would have been potentially lethal without a proper medical
144 intervention; otherwise PSAs were considered mild.
145 Current pharmacological treatment, if any, was
146 recorded, and we considered the use of lithium, mood
147 stabilizers, antipsychotics, and antidepressants as pri-
148 mary and adequate treatment for BD, either in mono- or
149 polytherapy. In addition, the presence of polypharma-
150 cotherapy, defined by current use of>3 psychotropic
151 compounds, was assessed.
152 All patients were then divided into 2 groups according
153 to the lifetime occurrence of at least 1 PSA: PSA patients
154 and non-PSA patients.
155 Statistical analyses were performed using the Statis-
156 tical Package for the Social Sciences (SPSS), version 22.
157 Multivariate analysis of variance (MANOVA) was used
158 to compare the 2 subgroups for continuous variables.
159 The MANOVA model proved to be valid (Wilks lambda
160 test, p< .001). Chi-square tests were used to compare
161 categorical variables, with Bonferroni post-hoc analysis.
162 A 2-tailed significance threshold was set at p< .05.
163 Results
164 Sociodemographic and clinical variables of the entire
165 sample and related subgroups are shown in Tables 1
166 and 2, respectively.
167
168
169
TABLE 1. Socio-demographic variables of the total sample and
patients with and without prior suicide attempt (PSA)
Variables Total sample PSA patients Non-PSA patients
N (%) 362 (100) 95(26.2) 267 (73.8)
Age (years, mean± SD) 48.6± 14.4 49.7± 13.8 48.2± 14.5
Gender (%)
Male 47.5 43.2 48.7
Female 52.5 56.8 51.3
Education (%)
Secondary school 16.9 20.9 15.6
High-school 51.3 48.4 52.9
University 29.1 27.5 29.1
Employment (%)
Employed 48.7 48.4 49.0
Unemployed 37.8 39.6 37.3
Retired 13.5 12.1 13.7
Co-habitation (%)
Family 45.7 46.1 45.8
Family of origin 24.7 22.5 25.6
Alone 22.9 22.5 22.7
Other 6.7 9.0 5.9
Marital status (%)
Single 43.0 38.0 45.2
Partner 42.1 41.3 41.9
Divorced 12.3 16.3 10.9
Values for categorical and continuous variables are expressed in percentages
and mean± SD, respectively.
TABLE 2. Clinical variables of the total sample and patients with
and without prior suicide attempt (PSA)
Variables
Total
sample
PSA
patients
Non-PSA
patients
Diagnosis
BD I 74.3 75.8 74.0
BD II 25.7 24.2 26.0
Age at onset (years, mean± SD) 28.7± 11.4 27.3± 10.1 29.2± 11.8
<18 years 12.8 15.1 11.7
≥18 years 87.2 84.9 88.3
Duration of illness (months,
mean± SD)
241.8± 155.6 274± 156.3 230.1± 154.1
Duration of untreated illness
(months, mean± SD)
58± 101.2 60.8± 99.6 55.9± 100.9
Family history of psychiatric disorder (%) 65.6 67.0 64.9
Polarity of first episode
Depressive first episode (%) 57.6 67.4* 53.9
Elevated first episode (%) 42.4 32.6 46.1*
Duration of most recent episode
(days, mean± SD)
40.6± 54.9 42.0± 58.5 40.3± 54.0
Psychiatric hospitalizations
(lifetime #, mean± SD)
3.1± 5.1 5.1± 8.4** 2.3± 2.7
Involuntary commitments
(lifetime #, mean± SD)
0.6± 1.4 0.5± 1.4 0.6± 1.4
Psychosis (lifetime, %) 57.5 56.4 58.3
Subthreshold symptoms (lifetime, %) 47.0 49.4 46.6
Stressful life events (lifetime, %) 58.3 59.0 58.1
Psychiatric comorbidity (%)
Any 47.4 48.4 47.9
Generalized anxiety disorder 19.6 18.3 20.2
Panic disorder 6.5 3.2 7.8
Any anxiety disorder 29.1 25.5 30.5
Obsessive compulsive disorder 1.4 2.2 1.2
Personality disorder 5.1 7.5 4.3
Alcohol abuse 14.8 25.8* 11.0
Substance use disorder 17.1 19.1 16.5
Eating disorder 3.1 5.3* 1.9
Psychiatric poly-comorbidity 14.7 24.2* 11.5
Medical comorbidity (lifetime, %) 48.3 57.9 44.4
Psychosocial rehabilitation (lifetime, %) 12.7 20.9* 9.8
Global Assessment of Functioning
(current, mean± SD)
65.3± 14 62.5± 13.7 66.2± 14.0
Current treatment (%)
Mood stabilizers 73.2 75.6 72.1
Lithium 21.6 29.2* 19.0
Antipsychotics 82.1 83.5 82.3
Mood stabilizers + antipsychotics 59.8 63.3 59.0
Antidepressants 35.0 30.5 36.0
Psychotropic drugs
0–3 drugs 88.9 82.2 91.2*
≥4 drugs 11.1 17.8* 8.8
SA methods (%)
Self-poisoning 13.9 60.0 0.0
Cutting 4.1 17.5 0.0
Jumping 3.7 16.0 0.0
SA gravity (%)
Mild 9.4 42.7 0.0
Serious 12.6 57.3 0.0
Values for categorical and continuous variables are expressed in percentages
and mean± SD, respectively. Boldface indicates parameters with significant
differences between the 2 subgroups. *p< .05, **p< .001.
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170 In our sample, 95 patients had PSAs, slightly above one-
171 quarter of the total sample (26.2%), with all patients having
172 survived their PSA. Reported methods were self-poisoning
173 (60%), followed by cutting (17.5%), jumping (16%), and
174 other modalities (eg, hanging, gas inhalation, voluntary car
175 accident, frostbite, electrocution). More than half of
176 patients with PSA had at least 1 serious PSA (57.3%).
177 Patients withmore than 1 PSA comprised 7.9%of the entire
178 sample, and almost one-third (31.8%) of the PSA subgroup.
179 The PSA and non-PSA subgroups were similar in
180 respect to sociodemographic variables, with no statisti-
181 cally significant difference in terms of gender, education,
182 marital status, employment, or cohabitation.
183 With respect to clinical variables (Figure 1), patients
184 with versus without PSA more frequently had depressive
185 polarity at their first mood episode (67.4 vs 53.9%;
186 χ2 = 8.5, df = 3; p = .03).
187 The number of lifetime psychiatric hospitalizations
188 was higher in patients with versus without PSA (5.1± 8.4
189 vs 2.3±2.7; F = 78.8, p< .001). However, these sub-
190 groups did not have any statistically significant differ-
191 ence in terms of involuntary commitment.
192 The PSA and non-PSA subgroups did not show a
193 statistically significant difference regarding general
194 psychiatric comorbidity, even though PSA patients
195 reported to suffer more frequently from psychiatric
196 poly-comorbidity (24.2% vs 11.5%; χ2 = 8.6, df = 1;
197 p = .004). Additionally, the PSA group more frequently
198 reported comorbid alcohol abuse disorder, either current
199 or lifetime (25.8% vs 11.0%; χ2 = 11.4, df = 1;
200 p = .001), and eating disorders (5.3% vs 1.9%; p< .05).
201 Focusing on psychiatric treatment, polypharma-
202 cotherapy was more commonly present in PSA vs non-
203 PSA patients (17.8% vs 8.8%; χ2 = 5.4, df = 1; p = .03).
204 Moreover, the use of lithium as mood stabilizer was
205 higher in PSA compared with non-PSA patients (29.2 vs
206 19.0; χ2 = 4.0, df = 1; p = .05). There was no other
207 statistically significant pharmacotherapy difference in
208 patients with versus without PSA.
209 Finally, patients with versus without PSA more
210 frequently needed, in their lifetime, psychosocial rehabi-
211 litation (20.9% vs 9.8%; χ2 = 7.3, df = 1; p = .007).
212 In contrast, patients with versus without PSA did not
213 significantly differ in terms of BD subtype, age at onset,
214 duration of illness, DUI, psychiatric family history,
215 duration of last mood episode, stressful life events,
216 subthreshold symptoms, or GAF score.
217 Discussion
218 In our sample, more than 1 in 4 BD patients (26.2%) had
219 PSA. This finding is consistent with prior reports1,31,32
220 and highlights the strong association between BD and
221 PSA. Some studies, such as the Systematic Treatment
222 Enhancement Program for Bipolar Disorder (STEP-BD)
223(PSA prevalence of 36%)13 and a previous collaborative
224investigation of our group, which was conducted on an
225American sample (PSA rate of 30%),6 showed higher
226frequencies. On the other hand, a lower PSA frequency
227emerged in some studies, such as a Korean investigation
228that reported a PSA rate of 13.1% in BD inpatients.33
229Novick et al10 conducted a meta-analysis of 24 prospec-
230tive studies with a follow-up period ranging from
23118 months to 44 years, and observed a mean suicide
232attempt frequency of 23.8% in BD-I and 19.8% in BD-II
233patients. In our sample, a similar rate of PSA in BD-I
234and BD-II subjects emerged, as previously reported in
235collaborative studies of our group6,7,34 and in other
236reports.4,10,13,20,31,35–40 However, some studies have
237variably reported PSA rates in relation to BD subtype,
238with a higher PSA rate in BD-I41–43 or BD-II.33,44
239According to the above-mentioned results, self-
240poisoning (ie, overdose) represented the most common
241PSA method (60%), which is consistent with most prior
242studies. For instance, Schaffer et al,1 in the International
243Society for Bipolar Disorders (ISBD) Task Force report,
244found self-poisoning being used in an overall wide range
245(29.8%–80.1%), with studies documenting lower
246rates in Asians33,45 and higher rates in patients from
247other countries.46,47 According to the same authors,
248the next most used PSA methods were as follows: cutting
249(5.6%–22.7%), hanging (0.7%–26.3%), jumping
250(4.8%–13.2%), drowning (0.2%–16.7%), gas inhalation
251(2.8%–5.7%), shooting (1.4%–4.2%), self-immolation
252(1.3%–2.1%), and intentional car accident (1.4%).1 In
253our study, cutting and jumping were the second and third
254most used PSA methods, with rates of 17.5% and 16%,
255respectively. Comparing these results with literature
256data, our observed rates of cutting seemed to be
257consistent with available studies, while rates of jumping
258were overrepresented.
259In our study, approximately one-third (31.8%) of
260patients with PSA had more than 1 PSA. This result is
261similar to the STEP-BD report,13 but lower compared to
262the study by Michaelis et al,48 which reported two-thirds
263of PSA patients having multiple PSAs.
264Over the past several years, several clinical character-
265istics have been extensively studied to find an association
266between BD and suicidal behavior. For instance, prior
267studies found depressive polarity at first mood episode
268was more frequently related to PSA,15,16,20,22,23,33,37,40
269and this finding was confirmed in the present sample.
270In addition, in a recent study from our group that
271analyzed the same sample divided into 2 subgroups in
272relation to the polarity at onset, it emerged that bipolar
273patients with a depressive versus elevated polarity at
274onset had a 2-fold risk of PSA.9 On the other hand,
275patients with a manic episode at onset were found to
276show a lower risk in other studies,36,49,50 even though
277they more frequently adopted violent PSA methods.51
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278 To our knowledge, this is the first study that has
279 specifically analyzed the burden of psychiatric polyco-
280 morbidity in relation to PSA, and this variable emerged
281 to be more frequently encountered in patients with PSA.
282 Such patients might suffer from a more severe form of
283 BD due to higher comorbidity burden, which could
284 contribute to increasing the PSA risk. Focusing on
285 specific comorbidities, in fact, higher PSA risk has been
286 previously associated with current and lifetime substance
287 use disorder.4,23,37,40,51,52 One report linked PSA risk
288 with alcohol or substance abuse only.47 In this respect,
289 a statistically significant correlation between PSA and
290 alcohol use disorder (but not substance use disorder)
291 emerged in our sample.
292 Anxiety disorder comorbidity has been strongly
293 associated with higher PSA risk.4,20,32,51,53 Nonetheless,
294 this was not confirmed in our report; our sample showed
295 similar rates between PSA and non-PSA patients, or
296 approximately 1 out of 2 patients.
297 Confirming what emerged in the present sample,
298 previous studies highlighted a correlation between
299 eating disorder comorbidity and PSA in BD.12,16,53
300 Indeed, eating disorders represent a risk factor per se
301 for suicidal behaviors,54 with the BD comorbidity
302 possibly increasing this risk.
303 One important goal of proper pharmacological treat-
304 ments is to prevent suicide.55 In our study, patients with
305 versus without PSA were more frequently treated with
306 lithium. This finding may seem to be in contrast with the
307 compound’s well established protective effect toward
308 suicidal behavior.56–58 The result, however, should be
309 interpreted as a consequence of the retrospective nature
310 of the study, and, therefore, lithium treatment could have
311 been prescribed following a PSA as a preventive strategy.
312 In relation to antidepressant drugs, our study did not
313 show any difference between patients with versus without
314 PSA, in contrast with some prior reports, where PSA
315 occurred more often in bipolar patients taking versus not
316 taking antidepressants.16,44
317 Our findings showed that complex pharmacotherapy
318 (>3 drugs/day at assessment) was more commonly
319 received by PSA patients, as reported in a recent study.16
320 This result might depend on the more frequent poly-
321 comorbidity observed in such patients. Additionally, the
322 occurrence of a PSA might have been the reason to add
323 another pharmacological treatment (eg, lithium).
324 In our sample, patients with versus without PSA
325 reported a higher lifetime number of psychiatric hospi-
326 talizations. Prior studies are discordant on this topic,
327 with some authors confirming2 and others not confirm-
328 ing16,21 our finding. The higher occurrence of psychia-
329 tric hospitalizations might be explained by the
330 association between predominant depressive polarity
331 and PSA, which was not evident in our sample but has
332 been reported in other studies,59–61 in light of the
333reported correlation between predominant depressive
334polarity and increased number of hospitalizations.62
335To our knowledge, ours is the first report to show that
336patients with versus without PSA more often had
337psychosocial rehabilitation. Since no difference between
338PSA versus non-PSA patients in relation to current
339subthreshold symptoms or GAF score emerged in our
340sample, a PSA might be considered an independent
341clinical reason to suggest the initiation of a psychosocial
342rehabilitation program. Alternatively, PSA patients
343might have a higher need for rehabilitation in light
344of the greater disease burden (eg, due to the more
345frequently associated comorbidities, as observed in our
346sample).
347In our sample, other clinical variables did not show
348any statistically significant difference between patients
349with versus without PSA, in contrast with prior reports,
350such as, for instance, an earlier AAO,12–14,16,18,33,63 a
351longer duration of disease,15,16 and a longer DUI,17,64
352which weremore commonly related to patients with PSA.
353Our PSA and non-PSA subgroups did not have any
354statistically significant difference in sociodemographic
355variables. Prior studies found that PSA patients were
356more frequently of female gender,12,15,16,22,42 even
357though death by suicide was associated with male
358gender3,5 and use of more violent methods.39
359In the interpretation of the aforementioned results,
360the followingmethodological limitations should be taken
361into consideration. First, due the nature of the study,
362all collected variables were obtained retrospectively and,
363therefore, are susceptible to recall bias. Additionally, the
364severity of suicide attempts was assessed by clinicians
365through a descriptive criterion, and not through a
366specific standardized scale. Moreover, the nature of
367episodes in which PSA occurred was not collected for all
368patients. A further limitation is that the present study
369was based on a cross-sectional analysis, with a long-
370itudinal assessment being potentially more beneficial for
371evaluation of further suicidal behaviors. In relation to
372statistical analysis, we did not perform a multivariate
373analysis of covariance because clinically relevant vari-
374ables, such as BD subtypes, age at onset, and DUI, did
375not show any difference between PSA subgroups. Finally,
376our sample mostly attended a university clinic, and this
377may limit the generalizability of our findings due to
378referral bias. Therefore, further investigation with a
379wider sample size is deemed necessary to confirm our
380results.
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